Quinton Oswald has over 25 years of international general management experience, including onsite assignments in the US, Europe and South Africa.
Mr Oswald was the chief executive of Notal Vision, a commercial stage ophthalmic home monitoring services provider with a focus on both wet and dry AMD. Prior to that, he was the chief executive of Neurotech, chief executive of SARcode Bioscience where he was instrumental in the clinical development of lifitegrast ophthalmic solution 5% (Xiidra®) for the treatment of dry eye disease and its subsequent sale to Shire PLC. Mr Oswald was also the vice president and business unit head for Genentech’s tissue growth and repair business, where he oversaw the highly successful commercial launch of Lucentis® (ranibizumab) for the treatment of wet AMD; and led the North American Ophthalmology business for Novartis which, in conjunction with QLT, pioneered Visudyne®.
